Analysis of FoxP3+ T-regulatory Cells and CD8+ T-cells in Ovarian Carcinoma: Location and Tumor Infiltration Patterns Are Key Prognostic Markers

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2014 Nov 4

PMID 25365237

Citations 26

Authors

Cecilia Hermans

David Anz

Jutta Engel

Thomas Kirchner

Stefan Endres

Doris Mayr

Affiliations

Soon will be listed here.

Abstract

Purpose: Tumor infiltrating CD4+CD25+FoxP3+ regulatory immune cells (Treg) have been associated with impaired anti-tumor immune response and unfavorable prognosis for patients affected by ovarian carcinoma, whereas CD8+ T-cells have been found to positively influence survival rates in a large panel of solid tumors. Recently, density, location and tumor infiltration patterns of the respective immune cell subtypes have been identified as key prognostic factors for different types of tumors.

Patients And Methods: We stained 210 human ovarian carcinoma samples immunhistochemically for FoxP3 and CD8 to identify the impact different immune cell patterns have on generally accepted prognostic variables as well as on overall survival.

Results: We found that FoxP3+ cells located within lymphoid aggregates surrounding the tumor were strongly associated with reduced survival time (P = 0.007). Central accumulation of CD8+ effector cells within the tumor bed shows a positive effect on survival (P = 0,001).

Conclusion: The distribution pattern of immune cells within the tumor environment strongly influences prognosis and overall survival time of patients with ovarian carcinoma.

Citing Articles

Unlocking the potential of immunotherapy in platinum-resistant ovarian cancer: rationale, challenges, and novel strategies.

Kefas J, Flynn M Cancer Drug Resist. 2024; 7:39.

PMID: 39534871 PMC: 11555186. DOI: 10.20517/cdr.2024.67.

Pro-inflammatory responses after peptide-based cancer immunotherapy.

Mahaki H, Ravari H, Kazemzadeh G, Lotfian E, Daddost R, Avan A Heliyon. 2024; 10(11):e32249.

PMID: 38912474 PMC: 11190603. DOI: 10.1016/j.heliyon.2024.e32249.

Epithelial ovarian cancer is infiltrated by activated effector T cells co-expressing CD39, PD-1, TIM-3, CD137 and interacting with cancer cells and myeloid cells.

Tassi E, Bergamini A, Wignall J, SantAngelo M, Brunetto E, Balestrieri C Front Immunol. 2023; 14:1212444.

PMID: 37868997 PMC: 10585363. DOI: 10.3389/fimmu.2023.1212444.

Crosstalk of Immune Cells and Platelets in an Ovarian Cancer Microenvironment and Their Prognostic Significance.

Pankowska K, Bedkowska G, Chociej-Stypulkowska J, Rusak M, Dabrowska M, Osada J Int J Mol Sci. 2023; 24(11).

PMID: 37298230 PMC: 10253437. DOI: 10.3390/ijms24119279.

Development and function of FOXP3+ regulators of immune responses.

Golzari-Sorkheh M, Zuniga-Pflucker J Clin Exp Immunol. 2023; 213(1):13-22.

PMID: 37085947 PMC: 10324550. DOI: 10.1093/cei/uxad048.

References

Wing K, Sakaguchi S . Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol. 2009; 11(1):7-13. DOI: 10.1038/ni.1818. View

Hori S, Nomura T, Sakaguchi S . Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003; 299(5609):1057-61. DOI: 10.1126/science.1079490. View

Fontenot J, Gavin M, Rudensky A . Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003; 4(4):330-6. DOI: 10.1038/ni904. View

Chen W, Jin W, Hardegen N, Lei K, Li L, Marinos N . Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med. 2003; 198(12):1875-86. PMC: 2194145. DOI: 10.1084/jem.20030152. View

Curiel T, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P . Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004; 10(9):942-9. DOI: 10.1038/nm1093. View

NORTH R, Bursuker I . Generation and decay of the immune response to a progressive fibrosarcoma. I. Ly-1+2- suppressor T cells down-regulate the generation of Ly-1-2+ effector T cells. J Exp Med. 1984; 159(5):1295-311. PMC: 2187300. DOI: 10.1084/jem.159.5.1295. View

Awwad M, NORTH R . Immunologically mediated regression of a murine lymphoma after treatment with anti-L3T4 antibody. A consequence of removing L3T4+ suppressor T cells from a host generating predominantly Lyt-2+ T cell-mediated immunity. J Exp Med. 1988; 168(6):2193-206. PMC: 2189164. DOI: 10.1084/jem.168.6.2193. View

Jacobs I, Davies A, Bridges J, Stabile I, Fay T, Lower A . Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. BMJ. 1993; 306(6884):1030-4. PMC: 1677033. DOI: 10.1136/bmj.306.6884.1030. View

Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M . Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995; 155(3):1151-64. View

10.

Ropponen K, Eskelinen M, Lipponen P, Alhava E, Kosma V . Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. J Pathol. 1997; 182(3):318-24. DOI: 10.1002/(SICI)1096-9896(199707)182:3<318::AID-PATH862>3.0.CO;2-6. View

11.

Shimizu Y, Kamoi S, Amada S, Hasumi K, Akiyama F, Silverberg S . Toward the development of a universal grading system for ovarian epithelial carcinoma. I. Prognostic significance of histopathologic features--problems involved in the architectural grading system. Gynecol Oncol. 1998; 70(1):2-12. DOI: 10.1006/gyno.1998.5051. View

12.

Zou W . Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer. 2005; 5(4):263-74. DOI: 10.1038/nrc1586. View

13.

Dunn G, Ikeda H, Bruce A, Koebel C, Uppaluri R, Bui J . Interferon-gamma and cancer immunoediting. Immunol Res. 2005; 32(1-3):231-45. DOI: 10.1385/ir:32:1-3:231. View

14.

Sato E, Olson S, Ahn J, Bundy B, Nishikawa H, Qian F . Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A. 2005; 102(51):18538-43. PMC: 1311741. DOI: 10.1073/pnas.0509182102. View

15.

Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, Mottram P . B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med. 2006; 203(4):871-81. PMC: 2118300. DOI: 10.1084/jem.20050930. View

16.

Beyer M, Schultze J . Regulatory T cells in cancer. Blood. 2006; 108(3):804-11. DOI: 10.1182/blood-2006-02-002774. View

17.

Wu Y, Borde M, Heissmeyer V, Feuerer M, Lapan A, Stroud J . FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell. 2006; 126(2):375-87. DOI: 10.1016/j.cell.2006.05.042. View

18.

Shevach E . From vanilla to 28 flavors: multiple varieties of T regulatory cells. Immunity. 2006; 25(2):195-201. DOI: 10.1016/j.immuni.2006.08.003. View

19.

Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C . Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006; 313(5795):1960-4. DOI: 10.1126/science.1129139. View

20.

Larmonier N, Marron M, Zeng Y, Cantrell J, Romanoski A, Sepassi M . Tumor-derived CD4(+)CD25(+) regulatory T cell suppression of dendritic cell function involves TGF-beta and IL-10. Cancer Immunol Immunother. 2006; 56(1):48-59. PMC: 11030031. DOI: 10.1007/s00262-006-0160-8. View